The Australia Diabetes Care Devices Market is expected to reach more than USD 0.7 billion by 2025, at a CAGR greater than 9%. Monitoring devices are anticipated to dominate the market during the forecast period, owing to the rising prevalence of diabetes and an increase in the number of device users in the country. There has been a significant rise in insulin delivery systems technology, from insulin injections to insulin pumps. Technological innovations and advances give many conveniences in measuring blood glucose levels.
Key Market Trends
Increasing Diabetes Population at high rate
The prevalence of diabetes in Australia has more than tripled between 1989-2019. In 2019, Australia had about 1.36 million diabetic patients. In 2019, Type-1 diabetes patients accounted for 8.97% of the total diabetic population in Australia. Due to the early age and longer diabetes duration, the youth is at risk of developing diabetes at a younger age, which lessens their quality of life, shortens life expectancy, and increases healthcare costs of the society. Hence, the demand for oral anti-diabetes drugs market has been on the rise, and its adoption rate is seen increasing, which has been driving the market. Also, with the increasing awareness among Type-2 diabetes patients worldwide, the demand for the Diabetes Devices market has been rising at a rapid pace.
Sensors Occupy the Highest Share in the Australia Continuous Glucose Monitoring Devices Segment
In the Australian CGM market, sensors are having the highest share. Since, 2016 Federal Election, the government has worked to subsidize continuous glucose monitoring (CGM) technology for patients with Type-1 diabetes. The Australian government now provides access to subsidized continuous glucose monitoring (CGM) products through the National Diabetes Services Scheme (NDSS). The different CGM systems available in Australia include Dexcom G5, MiniMed 640G, Medtronic 670G, and Guardian Connect CGM. The innovations in the Sensors market are driving the growth of the segment in the forecast period. Some of the innovations are Eversense CGM System, an implantable glucose sensor by Senseonics, Incorporated was launched in 2018. The advantage of the Eversense CGM System is that it can remain in place for up to three months, where the other CGMs sensors remain in place up to 3-10 days.
There have been constant innovations driven by manufacturers to compete in the market. The major players, such as Abbott and Medtronic, have undergone many mergers, acquisitions, and partnerships, to establish market dominance, while also adhering to organic growth strategies, which is evident from the R&D spending of these companies. The manufacturers of insulin delivery devices are spending a massive amount on the R&D of the devices. For example, in Feb 2020, Abbott and Insulet partnered to integrate Abbott's glucose-sensing technology with Insulet's tubeless system, the Omnipod Horizon Automated Insulin Delivery (AID) System (Omnipod Horizon System), to offer personalized automated insulin delivery and care for people living with diabetes.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support